Forimtamig

Evidence outlook · lead readout

NCT06055075 · Relapsed or Refractory Multiple Myeloma

The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.

NCT06055075: Although the record lists randomized allocation, this was a small, open-label study with no placebo or active comparator and only 19 participants. Its primary outcomes included clinical response measures and safety, but no results are posted to show whether any endpoint was met.